Named after the average length of the GI tract, 9 Meters’ larazotide is the first coeliac drug to enter Phase III trials. If things go to plan, larazotide could be approved by 2023, thereby overcoming the unmet needs that remain in this condition despite adherence to a gluten-free diet.